These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1061 related articles for article (PubMed ID: 16826400)

  • 1. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
    Griffiths RR; Richards WA; McCann U; Jesse R
    Psychopharmacology (Berl); 2006 Aug; 187(3):268-83; discussion 284-92. PubMed ID: 16826400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
    Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
    Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.
    Griffiths R; Richards W; Johnson M; McCann U; Jesse R
    J Psychopharmacol; 2008 Aug; 22(6):621-32. PubMed ID: 18593735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
    Griffiths RR; Johnson MW; Richards WA; Richards BD; Jesse R; MacLean KA; Barrett FS; Cosimano MP; Klinedinst MA
    J Psychopharmacol; 2018 Jan; 32(1):49-69. PubMed ID: 29020861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
    Griffiths RR; Johnson MW; Carducci MA; Umbricht A; Richards WA; Richards BD; Cosimano MP; Klinedinst MA
    J Psychopharmacol; 2016 Dec; 30(12):1181-1197. PubMed ID: 27909165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
    Garcia-Romeu A; Griffiths RR; Johnson MW
    Curr Drug Abuse Rev; 2014; 7(3):157-64. PubMed ID: 25563443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens.
    Reissig CJ; Carter LP; Johnson MW; Mintzer MZ; Klinedinst MA; Griffiths RR
    Psychopharmacology (Berl); 2012 Sep; 223(1):1-15. PubMed ID: 22526529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
    Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR
    Psychopharmacology (Berl); 2018 Feb; 235(2):521-534. PubMed ID: 29116367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
    Barrett FS; Johnson MW; Griffiths RR
    J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
    Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
    J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.
    Barrett FS; Griffiths RR
    Curr Top Behav Neurosci; 2018; 36():393-430. PubMed ID: 28401522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
    MacLean KA; Johnson MW; Griffiths RR
    J Psychopharmacol; 2011 Nov; 25(11):1453-61. PubMed ID: 21956378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying.
    Sweeney MM; Nayak S; Hurwitz ES; Mitchell LN; Swift TC; Griffiths RR
    PLoS One; 2022; 17(8):e0271926. PubMed ID: 36001643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response.
    Calder AE; Rausch B; Liechti ME; Holze F; Hasler G
    J Psychopharmacol; 2024 Oct; 38(10):873-886. PubMed ID: 39302087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of consciousness and mystical-type experiences after acute LSD in humans.
    Liechti ME; Dolder PC; Schmid Y
    Psychopharmacology (Berl); 2017 May; 234(9-10):1499-1510. PubMed ID: 27714429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-lasting subjective effects of LSD in normal subjects.
    Schmid Y; Liechti ME
    Psychopharmacology (Berl); 2018 Feb; 235(2):535-545. PubMed ID: 28918441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
    Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment.
    Turton S; Nutt DJ; Carhart-Harris RL
    Curr Drug Abuse Rev; 2014; 7(2):117-27. PubMed ID: 25563444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.